Semax cognitive claims: what the research actually supports

What did @karinasbiohacking actually say?

The creator calls semax "the brain boost you need" and rattles off a list of mechanisms: increased BDNF, reduced reactive oxygen species, neuroprotection, and new neuronal growth through synaptogenesis. That is a lot of claims packed into one short clip. To be fair, she is describing proposed mechanisms, not just asserting magic. But calling it the boost you "need" crosses from reporting into selling.

The transcript focuses on four specific biological effects: BDNF upregulation, antioxidant activity, neuroprotection of existing neurons, and synaptogenesis. The caption adds memory, attention, learning, and problem-solving benefits, plus the claim that semax is well-tolerated without hormonal impacts or stimulant crashes. We will look at each of these in turn, because they are not all equally supported by evidence.

Does the science back this up?

Some of it, yes, but mostly in animal models and small clinical studies, not large randomized controlled trials in healthy adults. That distinction matters enormously, and the creator skips over it entirely.

On BDNF: semax is a synthetic heptapeptide derived from ACTH(4-7), and rodent studies do show BDNF elevation in the brain after administration. Dolotov et al. (2006, Journal of Molecular Neuroscience) found semax increased BDNF and its receptor TrkB in rat brain tissue. That is real data. The leap to "it will increase BDNF in you" is a bigger claim than that study supports.

On reactive oxygen species: there is some evidence for antioxidant-adjacent activity, but this is not semax's primary documented mechanism and the evidence is thinner. On synaptogenesis: the creator says semax will "create new synapses." Animal data suggests neurotrophin signaling can influence synaptic plasticity, but direct evidence of semax driving synaptogenesis in humans is essentially absent from peer-reviewed literature.

What did they get wrong (or right)?

Let's be direct. The creator gets the BDNF mechanism mostly right as a documented effect in preclinical research. That is worth acknowledging. Semax has also been used clinically in Russia for stroke recovery and cognitive impairment, which lends some legitimacy to the neuroprotective framing (Gusev et al., 1997, Zhurnal Nevrologii i Psikhiatrii).

What she gets wrong, or at least badly incomplete:

• The evidence base is almost entirely preclinical or from patient populations with neurological deficits, not healthy people looking for optimization.
• Saying semax will "give you a lot of cognitive benefits" in a healthy person is a significant overreach. The caption claims improvements in "healthy individuals," but the strongest clinical data involves stroke and cognitive deficit patients, not biohackers with normal baselines.
• "Create new synapses" via synaptogenesis is stated as fact. It is closer to a hypothesis extrapolated from BDNF's general role in synaptic plasticity.
• The claim about lacking stimulant-like crashes or hormonal impacts is plausible but not rigorously tested in long-duration human trials.

What should you actually know?

Semax is not FDA-approved. In the United States it exists in a regulatory gray zone, available through compounding pharmacies or gray-market peptide suppliers. That context is completely absent from this video, and it matters if you are making a decision about using it.

The honest summary of the evidence: semax has interesting preclinical data, a plausible mechanism involving BDNF, and some clinical use history in Russia for neurological conditions. It does not have robust, double-blind, placebo-controlled trial data supporting cognitive enhancement in healthy adults. If you are expecting the kind of evidence behind, say, a prescription SSRI, it is not there yet.

Regulatory note: semax is not approved by the FDA for any indication. Compounded versions are not equivalent to any approved drug. Anyone considering peptide therapy should consult a licensed healthcare provider, not a TikTok video with 8,300 views.